Search

Displaying results 1931 - 1940 of 10000 in total
  1. Drug

    Benzyl alcohol

    go.drugbank.com/drugs/DB06770
    ApprovedInvestigational

    Mixtures: Skinsept pur - Lösung zur Anwendung auf der Haut, Skinsept color - Lösung zur Anwendung auf der Haut
  2. Target

    Thiosulfate:glutathione sulfurtransferase

    go.drugbank.com/bio_entities/BE0010200
    EnzymeHumans

    Thiosulfate:glutathione sulfurtransferase (TST) required to produce S-sulfanylglutathione (GSS(-)), a central intermediate in hydrogen sulfide metabolism (PubMed:24981631). Provides the link between the first step in mammalian H(2)S meta...

    Synonyms: KAT
  3. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. … Foreskin fibroblast-like stromal cells (FDSCs) are progenitors isolated from human tissue that can differentiate into various cell types [A32660].

  4. Drug

    Deferiprone

    go.drugbank.com/drugs/DB08826
    ApprovedInvestigational

    Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. … Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired.

    Categories: Compounds used in a research, industrial, or household settingProducts: HİERO 500 MG FİLM KAPLI TABLET, 100 ADET, FERRIPROX 500 MG FILM KAPLI TABLET, 100 ADET
  5. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. … Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms.

  6. Drug

    Tetraferric tricitrate decahydrate

    go.drugbank.com/drugs/DB14520
    ApprovedInvestigational

    Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.

    Categories: Drugs for Treatment of Hyperkalemia and Hyperphosphatemia
  7. Drug

    Trimethobenzamide

    go.drugbank.com/drugs/DB00662
    ApprovedInvestigational

    Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ).

    Mixtures: EMEDUR 200 MG SUPOZITUAR, 100 ADET, EMEDUR 200 MG SUPOZITUAR, 50 ADETProducts: VOMITIN KAPSÜL 250 MG, 20 ADET, VOMET 100 MG SUPPOZITUVAR , 5 ADET
  8. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    [A225836] As a result, highly sensitized individuals experience marked delays on transplant lists due to the challenges associated with procuring an HLA compatible donor graft. … [A225836] High levels of anti-HLA antibodies also contribute to poor graft survival.

  9. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction … It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.

    Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  10. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated … maintenance monotherapy resulted in a 22% reduction in the risk of death.